WVE Form 4: Director Receives RSUs and Options, Sells Shares Under 10b5-1
Rhea-AI Filing Summary
HENRY CHRISTIAN O, a director of Wave Life Sciences Ltd. (WVE), reported compensation and trading activity. The director was granted 12,700 restricted share units (RSUs) and 76,200 share options under the 2025 Non-Employee Director Compensation Policy, with both awards vesting 100% on the earlier of the companys 2026 annual general meeting or August 11, 2026. The reporting person also sold 9,670 ordinary shares pursuant to a Rule 10b5-1 trading plan adopted November 24, 2024, at a weighted-average price of $8.81 per share (sales ranged $8.45 to $9.03). Following these transactions the report lists 29,645 ordinary shares and 76,200 options beneficially owned, held directly.
Positive
- Director awards align with shareholder interests via 12,700 RSUs and 76,200 options under the 2025 Non-Employee Director Compensation Policy
- Sale executed under a Rule 10b5-1 trading plan, indicating the disposition was pre-planned and compliant with insider trading procedures
Negative
- Insider sale of 9,670 shares was reported, which reduced direct shareholdings to 29,645 ordinary shares
- Options carry an exercise price of $8.105, which may require future cash outlay if exercised
Insights
Insider awards and pre-planned sales indicate routine director compensation and liquidity management.
The filing shows a standard Non-Employee Director package combining RSUs and stock options that vest on a single forthcoming date, which aligns director and shareholder interests by linking pay to future service and share price performance. The reported sale of 9,670 shares was executed under a Rule 10b5-1 plan established in November 2024, suggesting the transaction was pre-planned rather than opportunistic. From a governance perspective this mix of immediate equity awards and a pre-established sale plan is consistent with common director compensation and liquidity practices and does not alone indicate unusual governance risk.
Transactions are modest in size and appear routine; limited direct market impact is expected.
The director received 12,700 RSUs and 76,200 options with an exercise price shown at $8.105 for the options, and completed sales of 9,670 shares at a weighted-average price of $8.81. The disclosed sale price range of $8.45 to $9.03 and the use of a 10b5-1 plan reduce signaling around timing. Reported direct beneficial ownership after the activity is 29,645 ordinary shares and 76,200 options. Absent additional context on outstanding share count or material holdings relative to company capitalization, these transactions appear routine and are unlikely to be materially market moving on their own.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 9,670 | $8.81 | $85K |
| Grant/Award | Share Option (right to buy) | 76,200 | $0.00 | -- |
| Grant/Award | Ordinary Shares | 12,700 | $0.00 | -- |
Footnotes (1)
- The reporting person was granted this restricted share unit award (RSU) pursuant to the 2025 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 24, 2024. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $8.45 to $9.03 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The reporting person was granted this option pursuant to the 2025 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026
